All News

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.

Researchers studied the effect of wildfires on mental health in California from 2011 to 2018.

Recent studies on daylight saving time’s association with increased health risks have heightened the debate on whether to observe the biannual event or switch to one universal time.

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

Medical spending on pediatric mental health conditions accounted for 46.6% of all pediatric medical spending in 2021.

The implementation of targeted educational interventions might improve knowledge gaps, which pose great risk to patients, in type 2 diabetes (T2D) management.

N-3 polyunsaturated fatty acids (PUFAs) are essential nutrients, especially during pregnancy as they support neurodevelopment in offspring and improve pregnancy outcomes.

Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Test your pharmacy news knowledge with our weekly quiz.

A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.

The biosimilar represents a comprehensive, accessible, and high-quality treatment option for patients in the US treated with tocilizumab.

The statement says the agency is talking with CMS to initiate new flexibilities, but multiple advocacy groups have said it’s not nearly enough.

Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.

Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.

Dexcom's Stelo will be available in summer 2024.

The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Test your pharmacy news knowledge with our weekly quiz: February 26 to March 1

Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.

Physician assistants have pulled well ahead of pharmacists in a recent listing of top jobs in the health care profession.